Treatment-resistant depression: therapeutic trends, challenges, and future directions, Patient Prefer Adherence, vol.6, pp.369-388, 2012. ,
, Diagnostic and statistical manual of mental disorders, 5th edn, American Psychiatric Association, 2013.
Brain-derived neurotrophic factor and neuropsychiatric disorders, Pharmacol Rev, vol.64, pp.238-258, 2012. ,
BDNF -a key transducer of antidepressant effects, Neuropharmacology, vol.102, pp.72-79, 2016. ,
Escitalopram and NHT normalized stress-induced anhedonia and molecular neuroadaptations in a mouse model of depression, PLoS One, vol.12, 2017. ,
Plasminogen activator Inhibitor-1 gene-deficient mice, J Clin Invest, vol.92, pp.2746-2755, 1993. ,
Physiological consequences of loss of plasminogen activator gene function in mice, Nature, vol.368, pp.419-424, 1994. ,
Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene, Science, vol.301, pp.386-389, 2003. ,
The role of BDNF and its receptors in depression and antidepressant drug action: reactivation of developmental plasticity, Dev Neurobiol, vol.70, pp.289-297, 2010. ,
Ventromedial prefrontal cortex regulates depressive-like behavior and rapid eye movement sleep in the rat, Neuropharmacology, vol.86, pp.125-132, 2014. ,
Escitalopram or novel herbal mixture treatments during or following exposure to stress reduce anxiety-like behavior through corticosterone and BDNF modifications, PLoS One, vol.9, 2014. ,
Effects of chronic fluoxetine in animal models of anxiety and depression, Neuropsychopharmacology, vol.29, pp.1321-1330, 2004. ,
Mechanisms of antidepressant resistance, Front Pharmacol, vol.4, p.146, 2013. ,
Younger, premenopausal women with major depressive disorder have more abdominal fat and increased serum levels of prothrombotic factors: implications for greater cardiovascular risk, Metabolism, vol.54, pp.918-924, 2005. ,
Role of epigenetic factors in the development of mental illness throughout life, Neurosci Res, vol.102, pp.56-66, 2016. ,
Monoamine neurocircuitry in depression and strategies for new treatments, Prog Neuro-Psychopharmacol Biol Psychiatry, vol.45, pp.54-63, 2013. ,
Prior exposure to the elevated plus-maze sensitizes mice to the acute behavioral effects of fluoxetine and phenelzine, 2003. ,
, Eur J Pharmacol, vol.459, pp.2874-2875
The fibrinolytic system: a new target for treatment of depression with psychedelics, Med Hypotheses, vol.100, pp.46-53, 2017. ,
Quality of life in major depressive disorder before/after multiple steps of treatment and one-year follow-up, Acta Psychiatr Scand, vol.131, pp.51-60, 2015. ,
Early and late-onset effect of chronic stress on vascular function in mice: a possible model of the impact of depression on vascular disease in aging, Am J Geriatr Psychiatry, vol.19, pp.335-346, 2011. ,
Serotonin transporter gene, stress and raphe-raphe interactions: a molecular mechanism of depression, Trends Neurosci, vol.35, pp.395-402, 2012. ,
Plasminogen activator Inhibitor-1 in depression: results from animal and clinical studies, Sci Rep, vol.6, p.30464, 2016. ,
Side effects of antidepressants: an overview, Cleve Clin J Med, vol.73, pp.351-353, 2006. ,
Relation of depressive mood to plasminogen activator inhibitor, tissue plasminogen activator, and fibrinogen levels in patients with versus without coronary heart disease, Am J Cardiol, vol.97, pp.1287-1291, 2006. ,
Overshadowed by the amygdala: the bed nucleus of the stria terminalis emerges as key to psychiatric disorders, Mol Psychiatry, vol.21, pp.450-463, 2016. ,
Regulation of cell survival by secreted Proneurotrophins, Science, vol.294, pp.1945-1948, 2001. ,
Gene-environment interaction in major depression: focus on experience-dependent biological systems, Front Psychiatry, vol.6, p.68, 2015. ,
Structural brain abnormalities in major depressive disorder: a selective review of recent MRI studies, J Affect Disord, vol.117, pp.1-17, 2009. ,
The yin and yang of neurotrophin action, Nat Rev Neurosci, vol.6, pp.603-614, 2005. ,
Plasminogen activator Inhibitor-1 is involved in impaired bone repair associated with diabetes in female mice, PLoS One, vol.9, 2014. ,
Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine, 2002. ,
, Ann Clin Psychiatry Off J Am Acad Clin Psychiatr, vol.14, pp.175-182
Associations between depressive symptoms and inflammatory/ hemostatic markers in women during the menopausal transition, Psychosom Med, vol.69, pp.124-130, 2007. ,
Increased hippocampal volume and gene expression following cognitive behavioral therapy in PTSD, Front Hum Neurosci, vol.7, 2013. ,
Major depressive disorder, Nat Rev Dis Primer, vol.2, p.16065, 2016. ,
Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity, Science, vol.306, pp.487-491, 2004. ,
Tissue plasminogen activator in the amygdala is critical for stressinduced anxiety-like behavior, Nat Neurosci, vol.6, pp.168-174, 2003. ,
BDNF as a biomarker for successful treatment of mood disorders: a systematic & quantitative meta-analysis, J Affect Disord, vol.174, pp.432-440, 2015. ,
Decreased serotonin levels associated with behavioral disinhibition in tissue plasminogen activator deficient (tPA?/?) mice, Brain Res, vol.1326, pp.135-142, 2010. ,
Neural circuits underlying the pathophysiology of mood disorders, Trends Cogn Sci, vol.16, pp.61-71, 2012. ,
Quality-of-life impairment in depressive and anxiety disorders, Am J Psychiatry, vol.162, pp.1171-1178, 2005. ,
Major depressive disorder: mechanism-based prescribing for personalized medicine, Neuropsychiatr Dis Treat, vol.11, pp.875-888, 2015. ,
Anti-apoptotic roles of plasminogen activator inhibitor-1 as a neurotrophic factor in the central nervous system, Thromb Haemost, vol.100, pp.1014-1020, 2008. ,
Ethopharmacological analysis of the open elevated plusmaze in mice, Behav Brain Res, vol.246, pp.76-85, 2013. ,
Role of plasminogen activator Inhibitor-1 in glucocorticoidinduced diabetes and osteopenia in mice, Diabetes, vol.64, pp.2194-2206, 2015. ,
Antidepressantlike effect of n-3 PUFAs in CUMS rats: role of tPA/PAI-1 system, Physiol Behav, vol.139, pp.210-215, 2015. ,
ProBDNF induces neuronal apoptosis via activation of a receptor complex of p75NTR and Sortilin, J Neurosci, vol.25, pp.5455-5463, 2005. ,
Role of tissue-type plasminogen activator and plasminogen activator inhibitor-1 in psychological stress and depression, Oncotarget, vol.8, pp.113258-113268, 2017. ,
Plasminogen activator inhibitor-1 gene is associated with major depression and antidepressant treatment response, Pharmacogenet Genomics, vol.18, pp.869-875, 2008. ,
Major depressive disorder in DSM-5: implications for clinical practice and research of changes from DSM-IV, Depress Anxiety, vol.31, pp.459-471, 2014. ,
Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study, Lancet, vol.390, pp.1211-1259, 2016. ,
Treatment-resistant depression: are animal models of depression fit for purpose?, Psychopharmacology, vol.232, pp.3473-3495, 2015. ,
Resistance to antidepressant drugs: the case for a more predisposition-based and less hippocampocentric research paradigm, Behav Pharmacol, vol.25, pp.352-371, 2014. ,
Activation of p75NTR by proBDNF facilitates hippocampal long-term depression, Nat Neurosci, vol.8, pp.1069-1077, 2005. ,
Meta-analyses of comparative efficacy of antidepressant medications on peripheral BDNF concentration in patients with depression, PLoS One, vol.12, 2017. ,
, Publisher's Note
, Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations